Clinical Profile and Outcome of Covid-19 Intensive Care Patients with Nosocomial Infections: A Single-Centred Experience from India
Main Article Content
Abstract
Background: Incidences of nosocomial infections in COVID-19 patients admitted to the intensive care unit (ICU) have become a common occurrence. Hospital-acquired infections (HAI) present increased mortality, cost-of-care, especially relevant in multidrug resistant (MDR) infections. Our study aimed to assess the clinical implications associated with HAI-infected COVID-19 patients.
Patients and Methods: We conducted retrospective single-centred study on ICU-admitted adult COVID-19 patients for a year i.e., 2021-22 at a tertiary Indian institute and collated data of HAI epidemiological, clinical and microbiological reports.
Results: Rate of HIA at our centre was estimated to be 10.29% and the mortality rate was 40.4%. 10 different organisms(Bacteria: 8, Fungi: 2) were detected in HAI, of which the incidence of Gram-negative infections (GNI) was highest i.e., 60% and that of Gram-positive infections (GPI)/Fungi (Fungi infected) were 20% each. Mortality was highest among GPI (36.67%), FI (13.46%), followed by and GPI (7.69%). Tocilizumab treatment decreased the risk of survivability with no significant difference in the treatment outcomes.
Conclusion: This study provides a comprehensive picture of nosocomial infections characteristics among COVID-19patients and provides insights regarding the impact of treatment on the outcome of these patients with suggestions for strategies. We found that critically ill patients with COVID- 19 are at a high risk of developing HAI, especially MDR mediated CLABSI and CAUTI. Clinicians must therefore be cautious and mindful during implementing protocols for management of infectious complications with COVID-19 patients.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Xie M, Chen Q. Insight into 2019 novel coronavirus—An updated interim review and lessons from SARS- CoV and MERS-CoV. International Journal of Infectious Diseases. 2020 May 1;94:119–124.
II. Moolla MS, Reddy K, Fwemba I, Nyasulu PS, Taljaard JJ, Parker A et al. Bacterial infection, antibiotic use and COVID-19: Lessons from the intensive care unit. South African Medical Journal. 2021 Jun 1;111(6):575–581.
III. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. The lancet respiratory medicine. 2020 May 1;8(5):506–276-517.
IV. Wee LE, Conceicao EP, Sim XY, Aung MK, Tan KY, Wong HM et al. Minimizing intra-hospital transmission of COVID-19: the role of social distancing. Journal of Hospital Infection. 2020 Jun 1;105(2):113–115.
V. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC et al. Prevalence and outcomes of Infection among patients in intensive care units in 2017. Jama. 2020 Apr 21;323(15):1478–14187.
VI. Risa E, Roach D, Budak JZ, Hebert C, Chan JD, Mani NS et al.Characterization of secondary bacterial infections and antibiotic use in mechanically ventilated patients with COVID-19 induced acute respiratory distress syndrome. Journal of Intensive Care Medicine. 2021 Oct;36(10):1167–1175.
VII. Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clinical Infectious Diseases. 2021 May 15;72(10):e533–541.
VIII. Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients with COVID- 28828919. Intensive care medicine. 2020 Nov;46(11):2071–2074.
IX. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta- analysis. Clinical microbiology 292 and infection. 2020 Dec 1;26(12):1622–1629.
X. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection. 2020 Aug 1;81(2):266–275.
XI. Clancy CJ, Nguyen MH. Coronavirus disease 2019, superinfections, and antimicrobial development: what can we expect?. Clinical Infectious Diseases. 2020 Nov 15;71(10):2736–2743.
XII. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Yet al. Clinical course and outcomes of critically ill patients with SARS- CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The lancet respiratory medicine. 2020 May 1;8(5):475–481.
XIII. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. 301 302 Pneumonia. 2021 Dec;13:1–5. 303 304.
XIV. Vaillancourt M, Jorth P. The unrecognized threat of secondary bacterial infections with COVID-19. MBio. 305 306 2020 Aug 25;11(4):e01806–01820. 307
XV. Castro MG, Ubiergo L, Vicino M, Cuevas G, Argarañá F. Rising incidence of Carbapenem resistant isolates: an Argentinian hospital's experience. More trouble in the aftermath of the COVID-19 pandemic. Iberoamerican Journal of Medicine. 2022 Apr 12;4(2):92–99.
XVI. Perez S, Innes GK, Walters MS, Mehr J, Arias J, Greeley R et al. Increase in hospital-acquired carbapenem- resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID- 19 admissions—New Jersey, February–July 2020. Morbidity and Mortality Weekly Report. 2020 Dec 314 12;69(48):1827.
XVII. Søgaard KK, Baettig V, Osthoff M, Marsch S, Leuzinger K, Schweitzer M et al. Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia. Journal of Intensive Care. 2021 Dec;9(1):1–10.
XVIII. Khurana S, Singh P, Sharad N, Kiro VV, Rastogi N, Lathwal A et al. Profileof co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian journal of medical microbiology. 2021Apr 1;39(2):147–153.
XIX. He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China. Infection Control & Hospital 323 Epidemiology. 2020
Aug;41(8):982–983.
XX. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist Met al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clinical infectious diseases. 2020 Nov 1;71(9):2459–68.
XXI. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerging infectious diseases. 2020 Nov;26(11):2694.
XXII. Maes M, Higginson E, Pereira-Dias J, Curran MD, Parmar S, Khokhar F, Cuchet-Lourenço D, et al. Ventilator- associated pneumonia in critically ill patients with COVID-19. Critical Care. 2021 Dec;25(1):1–11.
XXIII. Giacobbe DR, Battaglini D, Enrile EM, Dentone C, Vena A, Robba C, Ball L, Bartoletti M, Coloretti I,Di Bella S, Di Biagio A. Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study. Journal of clinical medicine. 2021 Feb 3;10(4):555.
XXIV. Meynaar IA, van Rijn S, Ottens TH, van Burgel ND, van Nieuwkoop C. Increased risk of central line- associated bloodstream infection in COVID-19 patients associated with dexamethasone but not with interleukin antagonists. Intensive Care Medicine. 2022 Jul;48(7):954–957.
XXV. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study.The Lancet Rheumatology. 2020 Aug 1;2(8):e474–484.
XXVI. The Impact of Antimicrobial Stewardship and Infection Control Interventions on Acinetobacter baumannii Resistance Rates in the ICU of a Tertiary Care Center in Lebanon; Nesrine A. Rizk, Nada Zahreddine, Nisrine Haddad, Antibiotics, July 2022;